Sertoli-Leydig cell tumors of the ovary and pregnancy

Robert L. Giuntoli, Maurice J. Webb

Research output: Contribution to journalArticle

Abstract

Sertoli-Leydig cell tumors represent less than 0.2% of all ovarian tumors and approximately 1% of ovarian malignancies discovered during pregnancy. Typically, ovarian malignancies during pregnancy are initially discovered as adnexal masses on routine prenatal ultrasonography. Because of the small risk of malignancy and the greater threat of torsion or obstruction of labor, persistent adnexal masses should be surgically excised at about 16 to 20 weeks of gestation. Approximately 5% of adnexal masses are malignant. Evaluation of the pathologic features is essential to determine the surgical and postoperative management of gravid women with a Sertoli-Leydig cell tumor of the ovary. Well-differentiated tumors may be treated adequately with unilateral salpingo-oophorectomy. Appropriate staging is required for tumors that are less differentiated. In both gravid and non-pregnant women, most Sertoli-Leydig cell tumors are confined to the ovary. In cases of tumors of advanced stage or grade, chemotherapy should at least be considered.

Original languageEnglish (US)
Pages (from-to)134-139
Number of pages6
JournalCME Journal of Gynecologic Oncology
Volume7
Issue number2
StatePublished - Jul 2002
Externally publishedYes

Fingerprint

Pregnancy
Sertoli-Leydig Cell Tumor
Neoplasms
Prenatal Ultrasonography
Ovariectomy
Androblastoma of ovary
Ovary
Drug Therapy

Keywords

  • Management
  • Pregnancy
  • Sertoli-Leydig cell tumor

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Sertoli-Leydig cell tumors of the ovary and pregnancy. / Giuntoli, Robert L.; Webb, Maurice J.

In: CME Journal of Gynecologic Oncology, Vol. 7, No. 2, 07.2002, p. 134-139.

Research output: Contribution to journalArticle

Giuntoli, RL & Webb, MJ 2002, 'Sertoli-Leydig cell tumors of the ovary and pregnancy', CME Journal of Gynecologic Oncology, vol. 7, no. 2, pp. 134-139.
Giuntoli, Robert L. ; Webb, Maurice J. / Sertoli-Leydig cell tumors of the ovary and pregnancy. In: CME Journal of Gynecologic Oncology. 2002 ; Vol. 7, No. 2. pp. 134-139.
@article{a691e20b78ae4832a94a0df2704e663b,
title = "Sertoli-Leydig cell tumors of the ovary and pregnancy",
abstract = "Sertoli-Leydig cell tumors represent less than 0.2{\%} of all ovarian tumors and approximately 1{\%} of ovarian malignancies discovered during pregnancy. Typically, ovarian malignancies during pregnancy are initially discovered as adnexal masses on routine prenatal ultrasonography. Because of the small risk of malignancy and the greater threat of torsion or obstruction of labor, persistent adnexal masses should be surgically excised at about 16 to 20 weeks of gestation. Approximately 5{\%} of adnexal masses are malignant. Evaluation of the pathologic features is essential to determine the surgical and postoperative management of gravid women with a Sertoli-Leydig cell tumor of the ovary. Well-differentiated tumors may be treated adequately with unilateral salpingo-oophorectomy. Appropriate staging is required for tumors that are less differentiated. In both gravid and non-pregnant women, most Sertoli-Leydig cell tumors are confined to the ovary. In cases of tumors of advanced stage or grade, chemotherapy should at least be considered.",
keywords = "Management, Pregnancy, Sertoli-Leydig cell tumor",
author = "Giuntoli, {Robert L.} and Webb, {Maurice J.}",
year = "2002",
month = "7",
language = "English (US)",
volume = "7",
pages = "134--139",
journal = "CME Journal of Gynecologic Oncology",
issn = "1219-9087",
publisher = "Primed-X Press",
number = "2",

}

TY - JOUR

T1 - Sertoli-Leydig cell tumors of the ovary and pregnancy

AU - Giuntoli, Robert L.

AU - Webb, Maurice J.

PY - 2002/7

Y1 - 2002/7

N2 - Sertoli-Leydig cell tumors represent less than 0.2% of all ovarian tumors and approximately 1% of ovarian malignancies discovered during pregnancy. Typically, ovarian malignancies during pregnancy are initially discovered as adnexal masses on routine prenatal ultrasonography. Because of the small risk of malignancy and the greater threat of torsion or obstruction of labor, persistent adnexal masses should be surgically excised at about 16 to 20 weeks of gestation. Approximately 5% of adnexal masses are malignant. Evaluation of the pathologic features is essential to determine the surgical and postoperative management of gravid women with a Sertoli-Leydig cell tumor of the ovary. Well-differentiated tumors may be treated adequately with unilateral salpingo-oophorectomy. Appropriate staging is required for tumors that are less differentiated. In both gravid and non-pregnant women, most Sertoli-Leydig cell tumors are confined to the ovary. In cases of tumors of advanced stage or grade, chemotherapy should at least be considered.

AB - Sertoli-Leydig cell tumors represent less than 0.2% of all ovarian tumors and approximately 1% of ovarian malignancies discovered during pregnancy. Typically, ovarian malignancies during pregnancy are initially discovered as adnexal masses on routine prenatal ultrasonography. Because of the small risk of malignancy and the greater threat of torsion or obstruction of labor, persistent adnexal masses should be surgically excised at about 16 to 20 weeks of gestation. Approximately 5% of adnexal masses are malignant. Evaluation of the pathologic features is essential to determine the surgical and postoperative management of gravid women with a Sertoli-Leydig cell tumor of the ovary. Well-differentiated tumors may be treated adequately with unilateral salpingo-oophorectomy. Appropriate staging is required for tumors that are less differentiated. In both gravid and non-pregnant women, most Sertoli-Leydig cell tumors are confined to the ovary. In cases of tumors of advanced stage or grade, chemotherapy should at least be considered.

KW - Management

KW - Pregnancy

KW - Sertoli-Leydig cell tumor

UR - http://www.scopus.com/inward/record.url?scp=0036662830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036662830&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0036662830

VL - 7

SP - 134

EP - 139

JO - CME Journal of Gynecologic Oncology

JF - CME Journal of Gynecologic Oncology

SN - 1219-9087

IS - 2

ER -